STXBP1 encephalopathy mimicking as Rett syndrome: An overlooked entity

The syntaxin-binding protein 1 (STXBP1) encephalopathy represents a heterogeneous neurodevelopmental spectrum, manifesting as epileptic encephalopathies, intellectual disability, and autism-related phenotypes. It is a broad clinical entity encompassing a range of neurodevelopmental and epileptic disorders, including West syndrome, unclassified early-onset epileptic encephalopathy, Dravet syndrome, non-syndromic epilepsy, intellectual disability, autism spectrum disorder, and Rett-like syndrome. We present a case of a 4-year-old girl with global developmental delay, infantile-onset pharmacoresistant seizures, autistic features, and repetitive hand automatisms mimicking Rett syndrome. Targeted sequencing revealed a pathogenic de novo non-sense mutation in STXBP1, demonstrating striking Rett-like symptomatology without classic MECP2 mutations. The findings highlight three critical implications: (i) STXBP1 screening should be prioritized in Rett spectrum disorders with negative initial testing, (ii) hand stereotypies represent an underrecognized feature in STXBP1 encephalopathy, and (iii) precision diagnosis enables tailored therapeutic strategies and prognostic counseling. Our observations reinforce the necessity of broad genetic panels in neurodevelopmental disorders, particularly when phenotypic overlap obscures traditional diagnostic boundaries.
- Stamberger H, Nikanorova M, Willemsen MH, et al. STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy. Neurology. 2016;86(10):954-962. doi: 10.1212/wnl.0000000000002457
- Yamamoto T, Shimojima K, Yano T, et al. Loss-of-function mutations of STXBP1 in patients with epileptic encephalopathy. Brain Dev. 2016;38(3):280-284. doi: 10.1016/j.braindev.2015.09.004
- Hamdan FF, Piton A, Gauthier J, et al. De novo STXBP1 mutations in mental retardation and nonsyndromic epilepsy. Ann Neurol. 2009;65(6):748-753. doi: 10.1002/ana.21625
- Segawa M, Nomura Y. Rett syndrome. Curr Opin Neurol. 2005;18(2):97-104. doi: 10.1097/01.wco.0000162848.99154.9a
- Collins BE, Neul JL. Rett syndrome and MECP2 duplication syndrome: Disorders of MeCP2 dosage. Neuropsychiatr Dis Treat. 2022;18:2813-2835. doi: 10.2147/ndt.s371483
- Hong W, Haviland I, Pestana-Knight E, et al. CDKL5 deficiency disorder-related epilepsy: A review of current and emerging treatment. CNS Drugs. 2022;36(6):591-604. doi: 10.1007/s40263-022-00921-5
- Gonzalez JN, Goldman S, Carter MT, Bain JM. Rett-like phenotypes in HNRNPH2-related neurodevelopmental disorder. Genes (Basel). 2023;14(6):1154. doi: 10.3390/genes14061154
- Wong LC, Singh S, Wang HP, Hsu CJ, Hu SC, Lee WT. FOXG1- related syndrome: From clinical to molecular genetics and pathogenic mechanisms. Int J Mol Sci. 2019;20(17):4176. doi: 10.3390/ijms20174176
- Mercimek-Andrews S. STXBP1 encephalopathy with epilepsy. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. Seattle, WA: University of Washington, DC; 1993 Available from: http:// www.ncbi.nlm.nih.gov/books/nbk396561 [Last accessed on 2025 Aug 03].
- Yuge K, Iwama K, Yonee C, et al. A novel STXBP1 mutation causes typical rett syndrome in a Japanese girl. Brain Dev. 2018;40(6):493-497. doi: 10.1016/j.braindev.2018.02.002
- Romaniello R, Saettini F, Panzeri E, Arrigoni F, Bassi MT, Borgatti R. A de-novo STXBP1 gene mutation in a patient showing the rett syndrome phenotype. Neuroreport. 2015;26(5):254-257. doi: 10.1097/wnr.0000000000000337
- Yoshida S, Amamoto M, Takahashi T, et al. Perampanel markedly improved clinical seizures in a patient with a rett-like phenotype and 960-kb deletion on chromosome 9q34.11 including the STXBP1. Clin Case Rep. 2022;10(5):e05811. doi: 10.1002/ccr3.5811
- Stamberger H, Weckhuysen S, De Jonghe P. STXBP1 as a therapeutic target for epileptic encephalopathy. Expert Opin Ther Targets. 2017;21(11):1027-1036. doi: 10.1080/14728222.2017.1386175
- STXBP1 Foundation. Clinical Trials and Observational Studies. Available from: https://www.stxbp1disorders.org/ clinicaltrialsandresearch [Last accessed on 2025 Aug 3].
- Capsida Receives FDA IND Clearance for its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy. News release. Capsida Biotherapeutics; 2025. Available from: https://capsida.com/ capsida-receives-fda-ind-clearance-for-its-first-in-class-iv-administered-gene-therapy-for-stxbp1-developmental-and-epileptic-encephalopathy [Last accessed on 2025 Aug 3].
- Freibauer A, Wohlleben M, Boelman C. STXBP1-related disorders: Clinical presentation, molecular function, treatment, and future directions. Genes (Basel). 2023;14(12):2179. doi: 10.3390/genes14122179